Varian Medical Systems (NYSE:VAR) will be announcing its earnings results after the market closes on Tuesday, January 23rd. Analysts expect the company to announce earnings of $1.00 per share for the quarter. Varian Medical Systems has set its FY18 guidance at $4.20-4.32 EPS.
Varian Medical Systems (NYSE:VAR) last posted its earnings results on Wednesday, October 25th. The medical equipment provider reported $1.09 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.19 by ($0.10). The firm had revenue of $739.00 million during the quarter, compared to analyst estimates of $741.69 million. Varian Medical Systems had a net margin of 8.85% and a return on equity of 23.68%. The firm’s revenue for the quarter was down 1.1% on a year-over-year basis. During the same period last year, the company posted $1.03 EPS. On average, analysts expect Varian Medical Systems to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.
Shares of Varian Medical Systems (NYSE VAR) opened at $108.49 on Tuesday. The firm has a market capitalization of $9,940.00, a price-to-earnings ratio of 39.31, a price-to-earnings-growth ratio of 3.30 and a beta of 0.68. Varian Medical Systems has a twelve month low of $76.94 and a twelve month high of $114.09.
In related news, EVP Kolleen T. Kennedy sold 2,018 shares of the stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $111.97, for a total transaction of $225,955.46. Following the transaction, the executive vice president now directly owns 27,749 shares in the company, valued at $3,107,055.53. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Timothy E. Guertin sold 10,000 shares of the stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $111.46, for a total value of $1,114,600.00. Following the transaction, the director now owns 2,161 shares in the company, valued at $240,865.06. The disclosure for this sale can be found here. Insiders have sold 111,727 shares of company stock worth $12,392,515 over the last quarter. 0.78% of the stock is currently owned by company insiders.
Several analysts have weighed in on VAR shares. Zacks Investment Research lowered Varian Medical Systems from a “hold” rating to a “sell” rating in a report on Friday, October 27th. Royal Bank of Canada set a $105.00 price objective on Varian Medical Systems and gave the company a “hold” rating in a research note on Thursday, November 30th. Citigroup increased their price objective on Varian Medical Systems from $119.00 to $121.00 and gave the company a “neutral” rating in a research note on Monday, October 30th. Evercore ISI assumed coverage on Varian Medical Systems in a research note on Wednesday, January 3rd. They set an “underperform” rating and a $100.00 price objective on the stock. Finally, BTIG Research reaffirmed a “hold” rating on shares of Varian Medical Systems in a research note on Sunday, October 29th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $100.44.
About Varian Medical Systems
Varian Medical Systems, Inc is a manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy.
Receive News & Ratings for Varian Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Varian Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.